The Safety of Intrathecal Therapy in the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)Phavina A Akhom, Adetola A. Kassim, Katie S. Gatwood et al.|Transplantation and Cellular Therapy|2025Cited by 2
The Impact of Telemedicine and Wearable Devices in Improving the Safety Profile of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: A Case-Control StudyTemitayo A. Akosile, Olalekan O. Oluwole, Bhagirathbhai Dholaria et al.|Transplantation and Cellular Therapy|2023Cited by 1
Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center AnalysisShakthi Bhaskar, Vivek Patel, Katherine E. Baker et al.|Blood|2023Cited by 0
Brexucabtagene Autoleucel in the Outpatient Setting, a Single Institution ExperienceDavid Morgan, Phavina A Akhom, Brian Hoeynck et al.|Transplantation and Cellular Therapy|2025Cited by 0
Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center AnalysisGrace Mercadante, Shakthi Bhaskar, Vivek Patel et al.|Transplantation and Cellular Therapy|2026Cited by 0